May 20, 2008 - Diasome Pharmaceuticals, a clinical stage diabetes therapeutics company, announced that four abstracts were accepted for publication at the 68th Annual Meeting of the American Diabetes Association, being held June 6 through June 10 at the Moscone Convention Center in San Francisco, Ca.All of the abstracts highlight HDV-Insulin, the Company’s proprietary oral and injectable insulin products. ...
...A 2-Week Randomized Active Comparator Study of Two HDV-Insulin Routes (SC and Oral) and SC Human Insulin in Patients with Type 1 Diabetes Mellitus....
...Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients with Type 2 Diabetes Mellitus...
...Hepatic-Directed Vesicle Insulin: Evaluation of a Novel Oral and Subcutaneous Insulin Delivery System in Animal Models of Diabetes... [PDF] Diasome Pharmaceuticals' Press Release -
